---
title: "NMN: Dosing & Vendor Prices — BodyHackGuide"
description: "NMN: dosing protocols, mechanism & side effects. Compare verified vendor prices."
lang: en
json-ld: |
  [
    {
      "@context": "https://schema.org",
      "@type": "BreadcrumbList",
      "itemListElement": [
        {
          "@type": "ListItem",
          "position": 1,
          "name": "Home",
          "item": "https://www.bodyhackguide.co/"
        },
        {
          "@type": "ListItem",
          "position": 2,
          "name": "Compounds",
          "item": "https://www.bodyhackguide.co/compare"
        },
        {
          "@type": "ListItem",
          "position": 3,
          "name": "NMN"
        }
      ]
    },
    {
      "@context": "https://schema.org",
      "@type": "MedicalWebPage",
      "name": "NMN",
      "description": "Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide derived from ribose and nicotinamide, serving as the direct biosynthetic precursor to nicotinamide adenine dinucleotide (NAD+) via a single enzymatic step catalyzed by nicotinamide mononucleotide adenylyltransferase (NMNAT). NMN is found in small quantities in foods including broccoli, cabbage, cucumber, edamame, avocado, tomato, and raw beef, typically in microgram-to-low-milligram quantities per serving — far below the 250-1000 mg doses used in supplementation research. The structure — a ribonucleotide composed of ribose-5-phosphate linked to nicotinamide via a beta-N-glycosidic bond — makes NMN one step closer to NAD+ in the biosynthetic pathway than nicotinamide or nicotinamide riboside (NR), which are two and one-plus-ATP step further removed respectively. NMN's rise from obscure biochemistry reagent to one of the most commercially prominent longevity supplements began with preclinical work in the Sinclair and Imai laboratories documenting NAD+-lowering effects of aging and NAD+-repletion benefits of NMN administration in mice. Mills et al. 2016 (PMID 28068222) demonstrated that 12 months of oral NMN (100-300 mg/kg) in aged mice prevented age-associated physiologic decline including weight gain, insulin sensitivity deterioration, eye function decline, muscle function decline, and bone density loss. Similar findings came from multiple rodent studies over 2013-2020 establishing NMN as a consistent NAD+-raising intervention with broad preclinical benefit across age-related pathologies. The first human pharmacokinetic study of NMN was conducted by Irie and colleagues in 2020, administering single oral doses of 100, 250, and 500 mg NMN to ten healthy Japanese men aged 40-60 and documenting dose-proportional increases in plasma NMN and its downstream metabolites with no serious adverse events — establishing oral NMN's basic safety and pharmacokinetics in humans. Yoshino and colleagues 2021 (PMID 33888596) conducted the first human efficacy RCT, randomizing 25 prediabetic postmenopausal women with overweight/obesity to 10 weeks of oral NMN 250 mg/day versus placebo. The trial documented significant improvement in skeletal muscle insulin sensitivity (measured by hyperinsulinemic-euglycemic clamp) with NMN versus placebo, and increased skeletal muscle expression of genes related to muscle remodeling. The Yoshino 2021 trial remains the landmark early human NMN efficacy study despite its small sample size. Subsequent human trials have examined NMN across a range of populations and outcomes with varying results: Yamamoto 2022 examined NMN in older adults with mixed metabolic outcomes; Pencina 2023provided a 6-week dose-ranging safety study; Connell et al. 2023conducted a meta-analysis of available NMN human trials through early 2023. The emerging human evidence base supports NMN's safety across tested dose ranges (up to 1,000 mg/day for short-term use in small trials) and provides suggestive but not yet definitive evidence for metabolic, cardiovascular, and musculoskeletal benefits. The evidence base remains substantially behind the marketing claims, with many commercial NMN products citing preclinical mouse data or extrapolating from NAD+ biology rather than demonstrating human RCT outcomes. Regulatory status: NMN was marketed in the US as a dietary supplement under DSHEA from approximately 2014 onward. In late 2022, the FDA issued a preliminary determination that NMN is not a lawful dietary supplement because it had been studied as a drug prior to being marketed as a supplement, potentially excluding it from DSHEA protection. This triggered significant industry concern and some reformulation. The regulatory situation has continued to evolve through 2025-2026 with industry litigation and FDA enforcement activity varying by product and distributor. As of early 2026, NMN remains widely available from many supplement retailers despite the regulatory uncertainty. NAD+ biochemistry context: NAD+ is a central coenzyme in cellular metabolism, participating in hundreds of enzymatic reactions spanning energy metabolism (as electron carrier in oxidative phosphorylation), DNA repair (as substrate for poly-ADP-ribose polymerase or PARP enzymes), and signaling (as substrate for sirtuins and CD38). Cellular NAD+ levels decline with aging across multiple tissues and organisms, with the decline implicated in age-associated mitochondrial dysfunction, impaired DNA repair, reduced sirtuin activity, and compromised cellular resilience. The NAD+ \"boosting\" hypothesis — that restoring youthful NAD+ levels through precursor supplementation could slow or reverse age-related decline — has driven extensive investment in NMN and the related NAD+ precursor nicotinamide riboside (NR, marketed as Niagen). NMN and NR are often discussed as competing or complementary precursors; both have human safety data and both raise NAD+ in humans, though the optimal dose, route, and clinical context remain areas of active research and commercial dispute. This entry covers NMN's biosynthesis and relationship to the NAD+ salvage pathway; the human and preclinical evidence base for metabolic, cardiovascular, and cognitive applications; dose-response considerations and the rational approach to supplementation; the oral versus sublingual versus injectable administration route debate; the evolving regulatory landscape; appropriate integration into complete longevity protocols alongside metformin, rapamycin (when available), NAD+, and lifestyle interventions; and honest framing that despite strong mechanistic rationale and good safety data, definitive evidence for meaningful longevity or healthspan extension in humans remains to be established.",
      "lastReviewed": "2026-05-04T11:35:46.999+00:00",
      "url": "https://www.bodyhackguide.co/compound/nmn",
      "author": {
        "@type": "Person",
        "name": "BioChonch",
        "url": "https://www.bodyhackguide.co/about",
        "jobTitle": "Founder & Lead Researcher",
        "sameAs": [
          "https://x.com/bodyhackguide",
          "https://reddit.com/r/BodyHackGuide",
          "https://reddit.com/r/BrainHackGuide",
          "https://reddit.com/r/Biohackingher"
        ],
        "worksFor": {
          "@type": "Organization",
          "name": "BodyHackGuide",
          "url": "https://www.bodyhackguide.co"
        }
      },
      "reviewedBy": {
        "@type": "Person",
        "name": "BioChonch",
        "url": "https://www.bodyhackguide.co/about",
        "jobTitle": "Founder & Lead Researcher",
        "sameAs": [
          "https://x.com/bodyhackguide",
          "https://reddit.com/r/BodyHackGuide",
          "https://reddit.com/r/BrainHackGuide",
          "https://reddit.com/r/Biohackingher"
        ],
        "worksFor": {
          "@type": "Organization",
          "name": "BodyHackGuide",
          "url": "https://www.bodyhackguide.co"
        }
      },
      "publisher": {
        "@type": "Organization",
        "name": "BodyHackGuide",
        "url": "https://www.bodyhackguide.co"
      },
      "mainContentOfPage": {
        "@type": "WebPageElement",
        "cssSelector": "main"
      },
      "about": {
        "@type": "Drug",
        "name": "NMN",
        "alternateName": [
          "Nicotinamide Mononucleotide",
          "beta-NMN",
          "β-NMN",
          "β-Nicotinamide mononucleotide",
          "NMN-C",
          "Uthever"
        ],
        "description": "Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide derived from ribose and nicotinamide, serving as the direct biosynthetic precursor to nicotinamide adenine dinucleotide (NAD+) via a single enzymatic step catalyzed by nicotinamide mononucleotide adenylyltransferase (NMNAT). NMN is found in small quantities in foods including broccoli, cabbage, cucumber, edamame, avocado, tomato, and raw beef, typically in microgram-to-low-milligram quantities per serving — far below the 250-1000 mg doses used in supplementation research. The structure — a ribonucleotide composed of ribose-5-phosphate linked to nicotinamide via a beta-N-glycosidic bond — makes NMN one step closer to NAD+ in the biosynthetic pathway than nicotinamide or nicotinamide riboside (NR), which are two and one-plus-ATP step further removed respectively. NMN's rise from obscure biochemistry reagent to one of the most commercially prominent longevity supplements began with preclinical work in the Sinclair and Imai laboratories documenting NAD+-lowering effects of aging and NAD+-repletion benefits of NMN administration in mice. Mills et al. 2016 (PMID 28068222) demonstrated that 12 months of oral NMN (100-300 mg/kg) in aged mice prevented age-associated physiologic decline including weight gain, insulin sensitivity deterioration, eye function decline, muscle function decline, and bone density loss. Similar findings came from multiple rodent studies over 2013-2020 establishing NMN as a consistent NAD+-raising intervention with broad preclinical benefit across age-related pathologies. The first human pharmacokinetic study of NMN was conducted by Irie and colleagues in 2020, administering single oral doses of 100, 250, and 500 mg NMN to ten healthy Japanese men aged 40-60 and documenting dose-proportional increases in plasma NMN and its downstream metabolites with no serious adverse events — establishing oral NMN's basic safety and pharmacokinetics in humans. Yoshino and colleagues 2021 (PMID 33888596) conducted the first human efficacy RCT, randomizing 25 prediabetic postmenopausal women with overweight/obesity to 10 weeks of oral NMN 250 mg/day versus placebo. The trial documented significant improvement in skeletal muscle insulin sensitivity (measured by hyperinsulinemic-euglycemic clamp) with NMN versus placebo, and increased skeletal muscle expression of genes related to muscle remodeling. The Yoshino 2021 trial remains the landmark early human NMN efficacy study despite its small sample size. Subsequent human trials have examined NMN across a range of populations and outcomes with varying results: Yamamoto 2022 examined NMN in older adults with mixed metabolic outcomes; Pencina 2023provided a 6-week dose-ranging safety study; Connell et al. 2023conducted a meta-analysis of available NMN human trials through early 2023. The emerging human evidence base supports NMN's safety across tested dose ranges (up to 1,000 mg/day for short-term use in small trials) and provides suggestive but not yet definitive evidence for metabolic, cardiovascular, and musculoskeletal benefits. The evidence base remains substantially behind the marketing claims, with many commercial NMN products citing preclinical mouse data or extrapolating from NAD+ biology rather than demonstrating human RCT outcomes. Regulatory status: NMN was marketed in the US as a dietary supplement under DSHEA from approximately 2014 onward. In late 2022, the FDA issued a preliminary determination that NMN is not a lawful dietary supplement because it had been studied as a drug prior to being marketed as a supplement, potentially excluding it from DSHEA protection. This triggered significant industry concern and some reformulation. The regulatory situation has continued to evolve through 2025-2026 with industry litigation and FDA enforcement activity varying by product and distributor. As of early 2026, NMN remains widely available from many supplement retailers despite the regulatory uncertainty. NAD+ biochemistry context: NAD+ is a central coenzyme in cellular metabolism, participating in hundreds of enzymatic reactions spanning energy metabolism (as electron carrier in oxidative phosphorylation), DNA repair (as substrate for poly-ADP-ribose polymerase or PARP enzymes), and signaling (as substrate for sirtuins and CD38). Cellular NAD+ levels decline with aging across multiple tissues and organisms, with the decline implicated in age-associated mitochondrial dysfunction, impaired DNA repair, reduced sirtuin activity, and compromised cellular resilience. The NAD+ \"boosting\" hypothesis — that restoring youthful NAD+ levels through precursor supplementation could slow or reverse age-related decline — has driven extensive investment in NMN and the related NAD+ precursor nicotinamide riboside (NR, marketed as Niagen). NMN and NR are often discussed as competing or complementary precursors; both have human safety data and both raise NAD+ in humans, though the optimal dose, route, and clinical context remain areas of active research and commercial dispute. This entry covers NMN's biosynthesis and relationship to the NAD+ salvage pathway; the human and preclinical evidence base for metabolic, cardiovascular, and cognitive applications; dose-response considerations and the rational approach to supplementation; the oral versus sublingual versus injectable administration route debate; the evolving regulatory landscape; appropriate integration into complete longevity protocols alongside metformin, rapamycin (when available), NAD+, and lifestyle interventions; and honest framing that despite strong mechanistic rationale and good safety data, definitive evidence for meaningful longevity or healthspan extension in humans remains to be established.",
        "activeIngredient": "NMN",
        "mechanismOfAction": "NMN functions as a direct precursor to NAD+ (nicotinamide adenine dinucleotide) through the NAD+ salvage pathway. The conversion requires a single enzymatic step catalyzed by NMNAT (nicotinamide mononucleotide adenylyltransferase), which adenylates NMN using ATP to produce NAD+. This contrasts with other NAD+ precursors: nicotinamide (NAM) requires two steps (NAM + PRPP → NMN via NAMPT, then NMN + ATP → NAD+); nicotinamide riboside (NR) requires two steps (NR + ATP → NMN via NRK1/2, then NMN + ATP → NAD+); tryptophan and nicotinic acid require multiple additional steps via the de novo or Preiss-Handler pathways. NMN's position one step before NAD+ theoretically provides more direct NAD+ supplementation than earlier precursors. However, a critical pharmacokinetic question has been whether orally administered NMN can reach tissues in intact form or whether it is degraded to nicotinamide during absorption and processing. Grozio et al. 2019identified the transporter Slc12a8 as an NMN-specific transporter on intestinal cell membranes, suggesting direct NMN uptake. However, Ratajczak et al. 2016 and other studies found that most orally-administered NMN is converted to nicotinamide riboside or nicotinamide before or during intestinal absorption, with the resulting nicotinamide serving as the systemic NAD+ precursor. This biochemistry has clinical implications: if NMN is primarily absorbed as nicotinamide, then NMN supplementation may be functionally similar to niacinamide supplementation (which is cheaper) unless the specific NMN form provides additional tissue-targeting or timing advantages. The Yoshino 2021 trial demonstrated functional insulin-sensitivity benefits from oral NMN in prediabetic women, suggesting that regardless of the specific absorbed form, supplementation achieves meaningful NAD+ elevation. Once NAD+ is elevated, the downstream effects are numerous and connected to multiple aging-relevant pathways: (1) Sirtuin activation — SIRT1, SIRT3, and other sirtuin deacetylases require NAD+ as a stoichiometric cofactor. Elevated NAD+ increases sirtuin activity, producing effects including deacetylation of PGC-1α (mitochondrial biogenesis), FOXO transcription factors (stress resistance), p53 (cell cycle regulation), histone H3K9 (chromatin modulation), and numerous other substrates. The mTOR-sirtuin-PGC1α-AMPK network is the central metabolic-sensing framework influenced by NAD+ elevation. (2) PARP substrate provision — PARP1, PARP2, and other poly-ADP-ribose polymerase enzymes use NAD+ in DNA damage response. Adequate NAD+ supports efficient DNA repair; NAD+ deficiency impairs repair and accelerates genomic instability. Aged cells have reduced PARP capacity partly due to NAD+ depletion. (3) CD38 competition — CD38, an ectoenzyme elevated in aging and inflammation, consumes NAD+ non-productively; its activity partly explains age-related NAD+ decline. Elevated NAD+ partially offsets CD38 consumption. (4) Mitochondrial function support — NAD+ is essential for oxidative phosphorylation, beta-oxidation, and the TCA cycle. Cellular NAD+ status influences mitochondrial capacity and efficiency. Age-related NAD+ decline contributes to mitochondrial dysfunction; NAD+ restoration partially reverses this. (5) Cellular metabolism integration — NAD+ and its reduced form NADH serve as the central redox couple linking fuel substrate oxidation to ATP production and biosynthetic pathways. (6) Vascular endothelial function — Martens et al. 2018demonstrated that NR (a related NAD+ precursor) improved aortic stiffness and endothelial function in middle-aged adults, effects attributable to NAD+-mediated sirtuin activation in endothelium. NMN is presumed to produce similar effects though specific NMN vascular trials are limited. (7) Stem cell function — preclinical evidence suggests NAD+ elevation supports adult stem cell function including muscle stem cells and intestinal stem cells, with possible regenerative implications. (8) Neuroprotection — neuronal NAD+ decline is implicated in age-related cognitive decline and neurodegenerative disease. NMN has shown neuroprotective effects in preclinical models, though human cognitive effect data is limited. (9) Immune function modulation — NAD+ influences immune cell metabolism, particularly T-cell function and macrophage polarization. Aging-associated immune dysfunction partly reflects NAD+ decline. (10) Circadian rhythm integration — NAD+ oscillates with circadian rhythm and is coupled to BMAL1-CLOCK circadian machinery; elevated NAD+ may support circadian robustness. The pharmacokinetic profile of oral NMN in humans (Irie 2020; Pencina 2023): oral NMN is absorbed and produces dose-proportional increases in plasma NMN (low levels, usually sub-micromolar), plasma NR (moderate), plasma nicotinamide (substantial), and intracellular NAD+ (variable by tissue). Plasma NMN peaks at 15-30 minutes post-dose; plasma nicotinamide and NR peaks at 30-60 minutes; NAD+ increases develop over hours-to-days and persist for days-weeks with continued dosing. Sublingual and intranasal routes have been proposed to bypass intestinal degradation and provide direct blood-borne NMN delivery, but evidence that these routes substantially outperform oral supplementation is limited.",
        "legalStatus": "Not approved for human use — research chemical",
        "warning": "For research purposes only. Not for human consumption."
      }
    },
    {
      "@context": "https://schema.org",
      "@type": "FAQPage",
      "mainEntity": [
        {
          "@type": "Question",
          "name": "Does NMN actually work in humans?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "The short answer is: probably yes for modest metabolic and functional benefits, but the evidence base for meaningful longevity or healthspan extension in humans remains preliminary. The Yoshino 2021 trial (PMID 33888596) documented improved insulin sensitivity in prediabetic postmenopausal women with 10 weeks of 250 mg/day NMN. Liao 2021 showed aerobic capacity improvements in recreational runners. Pencina 2023 (PMID 37378613) confirmed safety and dose-proportional NAD+ elevation. These and other small trials support that oral NMN elevates NAD+ and produces some functional benefits. However, meaningful lifespan or healthspan extension requires long-term trials (multiple years, large populations) that have not been conducted. NMN's evidence base currently supports it as a plausible metabolic and functional intervention with modest effect sizes, rather than a proven anti-aging therapy. See /compound/metformin for the most evidence-supported longevity-adjacent pharmaceutical."
          }
        },
        {
          "@type": "Question",
          "name": "Is NMN the same as NR (nicotinamide riboside)?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "NMN and NR are related but distinct NAD+ precursors with similar overall effects. NR is one step further from NAD+ in the biosynthetic pathway and requires conversion to NMN via the NRK1/2 enzymes before becoming NAD+. NMN converts to NAD+ via NMNAT in a single step. Both are absorbed orally and elevate NAD+; both have favorable safety profiles; both have human clinical trials supporting metabolic and functional benefits. Commercial positioning presents them as competing products, but the biochemistry suggests they are largely interchangeable with minor pharmacokinetic differences. NR (marketed as Tru Niagen) has a somewhat larger human clinical trial base due to earlier commercialization. NMN has received more Sinclair-lab-associated research. For practical purposes, either is a reasonable NAD+ precursor choice. Some practitioners rotate or combine them; evidence that this is superior to monotherapy is limited. See /compound/nad for related discussion."
          }
        },
        {
          "@type": "Question",
          "name": "What dose of NMN should I take?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "The standard dose range is 250-1,000 mg/day for most users. 250 mg/day is the Yoshino 2021 trial dose and is a reasonable entry dose. 500 mg/day is a common intermediate dose. 1,000 mg/day approaches the upper end of tested doses. Morning dosing is preferred to support circadian alignment. Take with water; food is optional. Doses above 1,000-2,000 mg/day have not shown additional benefit in available trials and may increase theoretical methyl-depletion concerns. For injectable NMN (compounded), 100-300 mg SC daily or several times weekly is typical but is not a standard consumer product. Quality matters — use reputable brands with third-party testing."
          }
        },
        {
          "@type": "Question",
          "name": "Will NMN help me live longer?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Honestly, unclear. Preclinical data in mice shows consistent lifespan extension of 5-15% with NMN and related NAD+ precursors, which is real but modest. Human lifespan extension requires trials that span multiple years in large populations, which have not been conducted for NMN. Short-term human trials (6-12 weeks) show modest metabolic and functional benefits, which plausibly translate to healthspan benefits if sustained, but this extrapolation is uncertain. Comparing NMN to interventions with stronger longevity evidence: exercise has robust epidemiologic and RCT-level evidence for reduced mortality; Mediterranean or plant-predominant diets have strong evidence; not smoking has very strong evidence; maintained social connection has good evidence. NMN is potentially additive to these foundational interventions but is not a replacement. The honest answer is that NMN may contribute modestly to healthspan-relevant physiology, but the magnitude of effect on lifespan in humans is unknown and likely small-to-moderate."
          }
        },
        {
          "@type": "Question",
          "name": "What is the best time of day to take NMN?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Morning dosing is generally recommended because NAD+ naturally peaks in the morning, aligning supplementation with endogenous circadian rhythm. NAD+ may produce mild alertness effects that can disrupt sleep for some users if taken in the evening. Take with water on an empty stomach or with a light meal. Some practitioners recommend splitting doses BID (morning + midday) for more stable exposure; this is reasonable for higher total doses. Avoid evening/night dosing for most users, particularly if you experience insomnia or restless sleep with NMN. If you take multiple supplements or medications, coordinate timing to avoid any pill-burden challenges but there are no significant timing-based interactions that require specific separation."
          }
        },
        {
          "@type": "Question",
          "name": "Does NMN cause any side effects?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "NMN has a favorable short-term safety profile. Reported side effects in clinical trials are generally mild and infrequent: GI upset (5-10%), occasional mild headache, mild insomnia with evening dosing, and rare flushing. No serious NMN-attributable adverse events have been reported in available trials. Long-term (>1 year) safety is less well-characterized because trials have generally been short. Theoretical concerns include methyl donor depletion (addressed by concurrent B-vitamin or TMG supplementation) and potential cancer substrate provision (avoid with active cancer). For most healthy adults, short-to-medium-term NMN use appears well-tolerated."
          }
        },
        {
          "@type": "Question",
          "name": "Is NMN still legal to buy in the US after the FDA determination?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "As of early 2026, NMN remains widely available from supplement retailers despite the FDA's late 2022 preliminary determination that NMN is not a lawful dietary supplement (because it had been studied as a drug prior to supplement marketing). The regulatory situation has continued to evolve with industry litigation, FDA enforcement discretion, and some product reformulation. Individual products have been pulled from some major retailers while remaining available from others. The legal status of buying NMN for personal use does not prevent individual purchase; the regulatory question primarily affects commercial marketing and distribution. Consumers can generally still purchase NMN from online retailers, compound pharmacies (with prescription), and some physical supplement stores. The long-term regulatory outcome remains uncertain."
          }
        },
        {
          "@type": "Question",
          "name": "Should I combine NMN with metformin or rapamycin?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Combinations of NMN with metformin or rapamycin (when available in our database) are popular in longevity-oriented protocols with plausible mechanistic rationale. Metformin activates AMPK and inhibits mitochondrial complex I; NMN elevates NAD+ and supports sirtuin activity; rapamycin inhibits mTORC1. These mechanisms converge on autophagy induction, improved metabolic flexibility, and anti-aging pathway activation. However, no controlled human trials have tested these combinations for longevity outcomes. Safety of combinations appears good based on individual agent profiles. For individuals pursuing comprehensive longevity pharmacology, the Sinclair/Attia-style stacks (metformin + NMN + rapamycin + resveratrol) are conceptually reasonable but evidence for marginal benefit of the combination over the most evidence-based single component (metformin) is absent. Individual choice with informed consent about the preliminary evidence state is appropriate."
          }
        },
        {
          "@type": "Question",
          "name": "Does NMN work better sublingually or in capsule form?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Controlled evidence comparing sublingual to oral NMN absorption and efficacy is limited. Theoretical arguments favor sublingual — bypassing intestinal degradation and first-pass metabolism. Practical evidence from available trials has primarily used oral capsule form and documented meaningful NAD+ elevation, suggesting oral absorption is adequate. Some users report subjectively faster onset with sublingual; others notice no difference. The added cost and practical inconvenience of sublingual forms may not be justified by the limited evidence of superior absorption. For most users, high-quality oral capsules are acceptable. For users specifically interested in sublingual, reputable sublingual powder products from vendors like DoNotAge, Renue, or Uthever are reasonable. Injectable NMN (compounded) provides the most direct systemic absorption but is not commercially available as a supplement and requires prescription and injection skill."
          }
        },
        {
          "@type": "Question",
          "name": "Can NMN help with energy, exercise performance, or cognitive function?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Modest evidence supports these applications. Liao et al. 2021 documented improved aerobic capacity (VO2max) in recreational runners taking NMN 300-1,200 mg/day for 6 weeks. Yoshino 2021 showed improved skeletal muscle gene expression related to muscle remodeling. Anecdotal reports of improved energy and cognitive clarity are common but not confirmed in controlled trials. Mechanistically, NAD+ is central to mitochondrial function and cellular energy metabolism, providing plausible basis for energy and performance benefits. For cognitive function specifically, preclinical evidence in aging mice shows NMN-mediated improvements in cerebromicrovascular function and cognitive performance. Human cognitive trials are limited. For individuals using NMN for energy or performance purposes, expect modest effects that may take weeks to develop. For exercise performance in already-trained healthy individuals, the effect magnitude is likely small. For older adults with age-related decline, effects may be more noticeable."
          }
        }
      ]
    },
    {
      "@context": "https://schema.org",
      "@type": "Organization",
      "@id": "https://www.bodyhackguide.co#organization",
      "name": "BodyHackGuide",
      "alternateName": "BHG",
      "url": "https://www.bodyhackguide.co",
      "logo": {
        "@type": "ImageObject",
        "url": "https://www.bodyhackguide.co/logo.png",
        "width": 512,
        "height": 512
      },
      "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.",
      "foundingDate": "2024",
      "founder": {
        "@id": "https://www.bodyhackguide.co/about#person"
      },
      "sameAs": [
        "https://x.com/bodyhackguide",
        "https://reddit.com/r/BodyHackGuide",
        "https://reddit.com/r/BrainHackGuide",
        "https://reddit.com/r/Biohackingher",
        "https://discord.gg/Mhq5UdRYBA"
      ],
      "knowsAbout": [
        "Peptide research",
        "Nootropic research",
        "Biohacking",
        "Compound dosing",
        "Vendor transparency"
      ],
      "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards",
      "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards",
      "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards"
    },
    {
      "@context": "https://schema.org",
      "@type": "MedicalWebPage",
      "name": "NMN",
      "description": "Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide derived from ribose and nicotinamide, serving as the direct biosynthetic precursor to nicotinamide adenine dinucleotide (NAD+) via a single enzymatic step catalyzed by nicotinamide mononucleotide adenylyltransferase (NMNAT). NMN is found in small quantities in foods including broccoli, cabbage, cucumber, edamame, avocado, tomato, and raw beef, typically in microgram-to-low-milligram quantities per serving — far below the 250-1000 mg doses used in supplementation research. The structure — a ribonucleotide composed of ribose-5-phosphate linked to nicotinamide via a beta-N-glycosidic bond — makes NMN one step closer to NAD+ in the biosynthetic pathway than nicotinamide or nicotinamide riboside (NR), which are two and one-plus-ATP step further removed respectively. NMN's rise from obscure biochemistry reagent to one of the most commercially prominent longevity supplements began with preclinical work in the Sinclair and Imai laboratories documenting NAD+-lowering effects of aging and NAD+-repletion benefits of NMN administration in mice. Mills et al. 2016 (PMID 28068222) demonstrated that 12 months of oral NMN (100-300 mg/kg) in aged mice prevented age-associated physiologic decline including weight gain, insulin sensitivity deterioration, eye function decline, muscle function decline, and bone density loss. Similar findings came from multiple rodent studies over 2013-2020 establishing NMN as a consistent NAD+-raising intervention with broad preclinical benefit across age-related pathologies. The first human pharmacokinetic study of NMN was conducted by Irie and colleagues in 2020, administering single oral doses of 100, 250, and 500 mg NMN to ten healthy Japanese men aged 40-60 and documenting dose-proportional increases in plasma NMN and its downstream metabolites with no serious adverse events — establishing oral NMN's basic safety and pharmacokinetics in humans. Yoshino and colleagues 2021 (PMID 33888596) conducted the first human efficacy RCT, randomizing 25 prediabetic postmenopausal women with overweight/obesity to 10 weeks of oral NMN 250 mg/day versus placebo. The trial documented significant improvement in skeletal muscle insulin sensitivity (measured by hyperinsulinemic-euglycemic clamp) with NMN versus placebo, and increased skeletal muscle expression of genes related to muscle remodeling. The Yoshino 2021 trial remains the landmark early human NMN efficacy study despite its small sample size. Subsequent human trials have examined NMN across a range of populations and outcomes with varying results: Yamamoto 2022 examined NMN in older adults with mixed metabolic outcomes; Pencina 2023provided a 6-week dose-ranging safety study; Connell et al. 2023conducted a meta-analysis of available NMN human trials through early 2023. The emerging human evidence base supports NMN's safety across tested dose ranges (up to 1,000 mg/day for short-term use in small trials) and provides suggestive but not yet definitive evidence for metabolic, cardiovascular, and musculoskeletal benefits. The evidence base remains substantially behind the marketing claims, with many commercial NMN products citing preclinical mouse data or extrapolating from NAD+ biology rather than demonstrating human RCT outcomes. Regulatory status: NMN was marketed in the US as a dietary supplement under DSHEA from approximately 2014 onward. In late 2022, the FDA issued a preliminary determination that NMN is not a lawful dietary supplement because it had been studied as a drug prior to being marketed as a supplement, potentially excluding it from DSHEA protection. This triggered significant industry concern and some reformulation. The regulatory situation has continued to evolve through 2025-2026 with industry litigation and FDA enforcement activity varying by product and distributor. As of early 2026, NMN remains widely available from many supplement retailers despite the regulatory uncertainty. NAD+ biochemistry context: NAD+ is a central coenzyme in cellular metabolism, participating in hundreds of enzymatic reactions spanning energy metabolism (as electron carrier in oxidative phosphorylation), DNA repair (as substrate for poly-ADP-ribose polymerase or PARP enzymes), and signaling (as substrate for sirtuins and CD38). Cellular NAD+ levels decline with aging across multiple tissues and organisms, with the decline implicated in age-associated mitochondrial dysfunction, impaired DNA repair, reduced sirtuin activity, and compromised cellular resilience. The NAD+ \"boosting\" hypothesis — that restoring youthful NAD+ levels through precursor supplementation could slow or reverse age-related decline — has driven extensive investment in NMN and the related NAD+ precursor nicotinamide riboside (NR, marketed as Niagen). NMN and NR are often discussed as competing or complementary precursors; both have human safety data and both raise NAD+ in humans, though the optimal dose, route, and clinical context remain areas of active research and commercial dispute. This entry covers NMN's biosynthesis and relationship to the NAD+ salvage pathway; the human and preclinical evidence base for metabolic, cardiovascular, and cognitive applications; dose-response considerations and the rational approach to supplementation; the oral versus sublingual versus injectable administration route debate; the evolving regulatory landscape; appropriate integration into complete longevity protocols alongside metformin, rapamycin (when available), NAD+, and lifestyle interventions; and honest framing that despite strong mechanistic rationale and good safety data, definitive evidence for meaningful longevity or healthspan extension in humans remains to be established.",
      "lastReviewed": "2026-05-04T11:35:46.999+00:00",
      "url": "https://www.bodyhackguide.co/compound/nmn",
      "author": {
        "@type": "Person",
        "name": "BioChonch",
        "url": "https://www.bodyhackguide.co/about",
        "jobTitle": "Founder & Lead Researcher",
        "sameAs": [
          "https://x.com/bodyhackguide",
          "https://reddit.com/r/BodyHackGuide",
          "https://reddit.com/r/BrainHackGuide",
          "https://reddit.com/r/Biohackingher"
        ],
        "worksFor": {
          "@type": "Organization",
          "name": "BodyHackGuide",
          "url": "https://www.bodyhackguide.co"
        }
      },
      "reviewedBy": {
        "@type": "Person",
        "name": "BioChonch",
        "url": "https://www.bodyhackguide.co/about",
        "jobTitle": "Founder & Lead Researcher",
        "sameAs": [
          "https://x.com/bodyhackguide",
          "https://reddit.com/r/BodyHackGuide",
          "https://reddit.com/r/BrainHackGuide",
          "https://reddit.com/r/Biohackingher"
        ],
        "worksFor": {
          "@type": "Organization",
          "name": "BodyHackGuide",
          "url": "https://www.bodyhackguide.co"
        }
      },
      "publisher": {
        "@type": "Organization",
        "name": "BodyHackGuide",
        "url": "https://www.bodyhackguide.co"
      },
      "mainContentOfPage": {
        "@type": "WebPageElement",
        "cssSelector": "main"
      },
      "about": {
        "@type": "Drug",
        "name": "NMN",
        "alternateName": [
          "Nicotinamide Mononucleotide",
          "beta-NMN",
          "β-NMN",
          "β-Nicotinamide mononucleotide",
          "NMN-C",
          "Uthever"
        ],
        "description": "Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide derived from ribose and nicotinamide, serving as the direct biosynthetic precursor to nicotinamide adenine dinucleotide (NAD+) via a single enzymatic step catalyzed by nicotinamide mononucleotide adenylyltransferase (NMNAT). NMN is found in small quantities in foods including broccoli, cabbage, cucumber, edamame, avocado, tomato, and raw beef, typically in microgram-to-low-milligram quantities per serving — far below the 250-1000 mg doses used in supplementation research. The structure — a ribonucleotide composed of ribose-5-phosphate linked to nicotinamide via a beta-N-glycosidic bond — makes NMN one step closer to NAD+ in the biosynthetic pathway than nicotinamide or nicotinamide riboside (NR), which are two and one-plus-ATP step further removed respectively. NMN's rise from obscure biochemistry reagent to one of the most commercially prominent longevity supplements began with preclinical work in the Sinclair and Imai laboratories documenting NAD+-lowering effects of aging and NAD+-repletion benefits of NMN administration in mice. Mills et al. 2016 (PMID 28068222) demonstrated that 12 months of oral NMN (100-300 mg/kg) in aged mice prevented age-associated physiologic decline including weight gain, insulin sensitivity deterioration, eye function decline, muscle function decline, and bone density loss. Similar findings came from multiple rodent studies over 2013-2020 establishing NMN as a consistent NAD+-raising intervention with broad preclinical benefit across age-related pathologies. The first human pharmacokinetic study of NMN was conducted by Irie and colleagues in 2020, administering single oral doses of 100, 250, and 500 mg NMN to ten healthy Japanese men aged 40-60 and documenting dose-proportional increases in plasma NMN and its downstream metabolites with no serious adverse events — establishing oral NMN's basic safety and pharmacokinetics in humans. Yoshino and colleagues 2021 (PMID 33888596) conducted the first human efficacy RCT, randomizing 25 prediabetic postmenopausal women with overweight/obesity to 10 weeks of oral NMN 250 mg/day versus placebo. The trial documented significant improvement in skeletal muscle insulin sensitivity (measured by hyperinsulinemic-euglycemic clamp) with NMN versus placebo, and increased skeletal muscle expression of genes related to muscle remodeling. The Yoshino 2021 trial remains the landmark early human NMN efficacy study despite its small sample size. Subsequent human trials have examined NMN across a range of populations and outcomes with varying results: Yamamoto 2022 examined NMN in older adults with mixed metabolic outcomes; Pencina 2023provided a 6-week dose-ranging safety study; Connell et al. 2023conducted a meta-analysis of available NMN human trials through early 2023. The emerging human evidence base supports NMN's safety across tested dose ranges (up to 1,000 mg/day for short-term use in small trials) and provides suggestive but not yet definitive evidence for metabolic, cardiovascular, and musculoskeletal benefits. The evidence base remains substantially behind the marketing claims, with many commercial NMN products citing preclinical mouse data or extrapolating from NAD+ biology rather than demonstrating human RCT outcomes. Regulatory status: NMN was marketed in the US as a dietary supplement under DSHEA from approximately 2014 onward. In late 2022, the FDA issued a preliminary determination that NMN is not a lawful dietary supplement because it had been studied as a drug prior to being marketed as a supplement, potentially excluding it from DSHEA protection. This triggered significant industry concern and some reformulation. The regulatory situation has continued to evolve through 2025-2026 with industry litigation and FDA enforcement activity varying by product and distributor. As of early 2026, NMN remains widely available from many supplement retailers despite the regulatory uncertainty. NAD+ biochemistry context: NAD+ is a central coenzyme in cellular metabolism, participating in hundreds of enzymatic reactions spanning energy metabolism (as electron carrier in oxidative phosphorylation), DNA repair (as substrate for poly-ADP-ribose polymerase or PARP enzymes), and signaling (as substrate for sirtuins and CD38). Cellular NAD+ levels decline with aging across multiple tissues and organisms, with the decline implicated in age-associated mitochondrial dysfunction, impaired DNA repair, reduced sirtuin activity, and compromised cellular resilience. The NAD+ \"boosting\" hypothesis — that restoring youthful NAD+ levels through precursor supplementation could slow or reverse age-related decline — has driven extensive investment in NMN and the related NAD+ precursor nicotinamide riboside (NR, marketed as Niagen). NMN and NR are often discussed as competing or complementary precursors; both have human safety data and both raise NAD+ in humans, though the optimal dose, route, and clinical context remain areas of active research and commercial dispute. This entry covers NMN's biosynthesis and relationship to the NAD+ salvage pathway; the human and preclinical evidence base for metabolic, cardiovascular, and cognitive applications; dose-response considerations and the rational approach to supplementation; the oral versus sublingual versus injectable administration route debate; the evolving regulatory landscape; appropriate integration into complete longevity protocols alongside metformin, rapamycin (when available), NAD+, and lifestyle interventions; and honest framing that despite strong mechanistic rationale and good safety data, definitive evidence for meaningful longevity or healthspan extension in humans remains to be established.",
        "activeIngredient": "NMN",
        "mechanismOfAction": "NMN functions as a direct precursor to NAD+ (nicotinamide adenine dinucleotide) through the NAD+ salvage pathway. The conversion requires a single enzymatic step catalyzed by NMNAT (nicotinamide mononucleotide adenylyltransferase), which adenylates NMN using ATP to produce NAD+. This contrasts with other NAD+ precursors: nicotinamide (NAM) requires two steps (NAM + PRPP → NMN via NAMPT, then NMN + ATP → NAD+); nicotinamide riboside (NR) requires two steps (NR + ATP → NMN via NRK1/2, then NMN + ATP → NAD+); tryptophan and nicotinic acid require multiple additional steps via the de novo or Preiss-Handler pathways. NMN's position one step before NAD+ theoretically provides more direct NAD+ supplementation than earlier precursors. However, a critical pharmacokinetic question has been whether orally administered NMN can reach tissues in intact form or whether it is degraded to nicotinamide during absorption and processing. Grozio et al. 2019identified the transporter Slc12a8 as an NMN-specific transporter on intestinal cell membranes, suggesting direct NMN uptake. However, Ratajczak et al. 2016 and other studies found that most orally-administered NMN is converted to nicotinamide riboside or nicotinamide before or during intestinal absorption, with the resulting nicotinamide serving as the systemic NAD+ precursor. This biochemistry has clinical implications: if NMN is primarily absorbed as nicotinamide, then NMN supplementation may be functionally similar to niacinamide supplementation (which is cheaper) unless the specific NMN form provides additional tissue-targeting or timing advantages. The Yoshino 2021 trial demonstrated functional insulin-sensitivity benefits from oral NMN in prediabetic women, suggesting that regardless of the specific absorbed form, supplementation achieves meaningful NAD+ elevation. Once NAD+ is elevated, the downstream effects are numerous and connected to multiple aging-relevant pathways: (1) Sirtuin activation — SIRT1, SIRT3, and other sirtuin deacetylases require NAD+ as a stoichiometric cofactor. Elevated NAD+ increases sirtuin activity, producing effects including deacetylation of PGC-1α (mitochondrial biogenesis), FOXO transcription factors (stress resistance), p53 (cell cycle regulation), histone H3K9 (chromatin modulation), and numerous other substrates. The mTOR-sirtuin-PGC1α-AMPK network is the central metabolic-sensing framework influenced by NAD+ elevation. (2) PARP substrate provision — PARP1, PARP2, and other poly-ADP-ribose polymerase enzymes use NAD+ in DNA damage response. Adequate NAD+ supports efficient DNA repair; NAD+ deficiency impairs repair and accelerates genomic instability. Aged cells have reduced PARP capacity partly due to NAD+ depletion. (3) CD38 competition — CD38, an ectoenzyme elevated in aging and inflammation, consumes NAD+ non-productively; its activity partly explains age-related NAD+ decline. Elevated NAD+ partially offsets CD38 consumption. (4) Mitochondrial function support — NAD+ is essential for oxidative phosphorylation, beta-oxidation, and the TCA cycle. Cellular NAD+ status influences mitochondrial capacity and efficiency. Age-related NAD+ decline contributes to mitochondrial dysfunction; NAD+ restoration partially reverses this. (5) Cellular metabolism integration — NAD+ and its reduced form NADH serve as the central redox couple linking fuel substrate oxidation to ATP production and biosynthetic pathways. (6) Vascular endothelial function — Martens et al. 2018demonstrated that NR (a related NAD+ precursor) improved aortic stiffness and endothelial function in middle-aged adults, effects attributable to NAD+-mediated sirtuin activation in endothelium. NMN is presumed to produce similar effects though specific NMN vascular trials are limited. (7) Stem cell function — preclinical evidence suggests NAD+ elevation supports adult stem cell function including muscle stem cells and intestinal stem cells, with possible regenerative implications. (8) Neuroprotection — neuronal NAD+ decline is implicated in age-related cognitive decline and neurodegenerative disease. NMN has shown neuroprotective effects in preclinical models, though human cognitive effect data is limited. (9) Immune function modulation — NAD+ influences immune cell metabolism, particularly T-cell function and macrophage polarization. Aging-associated immune dysfunction partly reflects NAD+ decline. (10) Circadian rhythm integration — NAD+ oscillates with circadian rhythm and is coupled to BMAL1-CLOCK circadian machinery; elevated NAD+ may support circadian robustness. The pharmacokinetic profile of oral NMN in humans (Irie 2020; Pencina 2023): oral NMN is absorbed and produces dose-proportional increases in plasma NMN (low levels, usually sub-micromolar), plasma NR (moderate), plasma nicotinamide (substantial), and intracellular NAD+ (variable by tissue). Plasma NMN peaks at 15-30 minutes post-dose; plasma nicotinamide and NR peaks at 30-60 minutes; NAD+ increases develop over hours-to-days and persist for days-weeks with continued dosing. Sublingual and intranasal routes have been proposed to bypass intestinal degradation and provide direct blood-borne NMN delivery, but evidence that these routes substantially outperform oral supplementation is limited.",
        "legalStatus": "Not approved for human use — research chemical",
        "warning": "For research purposes only. Not for human consumption."
      }
    },
    {
      "@context": "https://schema.org",
      "@type": "FAQPage",
      "mainEntity": [
        {
          "@type": "Question",
          "name": "Does NMN actually work in humans?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "The short answer is: probably yes for modest metabolic and functional benefits, but the evidence base for meaningful longevity or healthspan extension in humans remains preliminary. The Yoshino 2021 trial (PMID 33888596) documented improved insulin sensitivity in prediabetic postmenopausal women with 10 weeks of 250 mg/day NMN. Liao 2021 showed aerobic capacity improvements in recreational runners. Pencina 2023 (PMID 37378613) confirmed safety and dose-proportional NAD+ elevation. These and other small trials support that oral NMN elevates NAD+ and produces some functional benefits. However, meaningful lifespan or healthspan extension requires long-term trials (multiple years, large populations) that have not been conducted. NMN's evidence base currently supports it as a plausible metabolic and functional intervention with modest effect sizes, rather than a proven anti-aging therapy. See /compound/metformin for the most evidence-supported longevity-adjacent pharmaceutical."
          }
        },
        {
          "@type": "Question",
          "name": "Is NMN the same as NR (nicotinamide riboside)?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "NMN and NR are related but distinct NAD+ precursors with similar overall effects. NR is one step further from NAD+ in the biosynthetic pathway and requires conversion to NMN via the NRK1/2 enzymes before becoming NAD+. NMN converts to NAD+ via NMNAT in a single step. Both are absorbed orally and elevate NAD+; both have favorable safety profiles; both have human clinical trials supporting metabolic and functional benefits. Commercial positioning presents them as competing products, but the biochemistry suggests they are largely interchangeable with minor pharmacokinetic differences. NR (marketed as Tru Niagen) has a somewhat larger human clinical trial base due to earlier commercialization. NMN has received more Sinclair-lab-associated research. For practical purposes, either is a reasonable NAD+ precursor choice. Some practitioners rotate or combine them; evidence that this is superior to monotherapy is limited. See /compound/nad for related discussion."
          }
        },
        {
          "@type": "Question",
          "name": "What dose of NMN should I take?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "The standard dose range is 250-1,000 mg/day for most users. 250 mg/day is the Yoshino 2021 trial dose and is a reasonable entry dose. 500 mg/day is a common intermediate dose. 1,000 mg/day approaches the upper end of tested doses. Morning dosing is preferred to support circadian alignment. Take with water; food is optional. Doses above 1,000-2,000 mg/day have not shown additional benefit in available trials and may increase theoretical methyl-depletion concerns. For injectable NMN (compounded), 100-300 mg SC daily or several times weekly is typical but is not a standard consumer product. Quality matters — use reputable brands with third-party testing."
          }
        },
        {
          "@type": "Question",
          "name": "Will NMN help me live longer?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Honestly, unclear. Preclinical data in mice shows consistent lifespan extension of 5-15% with NMN and related NAD+ precursors, which is real but modest. Human lifespan extension requires trials that span multiple years in large populations, which have not been conducted for NMN. Short-term human trials (6-12 weeks) show modest metabolic and functional benefits, which plausibly translate to healthspan benefits if sustained, but this extrapolation is uncertain. Comparing NMN to interventions with stronger longevity evidence: exercise has robust epidemiologic and RCT-level evidence for reduced mortality; Mediterranean or plant-predominant diets have strong evidence; not smoking has very strong evidence; maintained social connection has good evidence. NMN is potentially additive to these foundational interventions but is not a replacement. The honest answer is that NMN may contribute modestly to healthspan-relevant physiology, but the magnitude of effect on lifespan in humans is unknown and likely small-to-moderate."
          }
        },
        {
          "@type": "Question",
          "name": "What is the best time of day to take NMN?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Morning dosing is generally recommended because NAD+ naturally peaks in the morning, aligning supplementation with endogenous circadian rhythm. NAD+ may produce mild alertness effects that can disrupt sleep for some users if taken in the evening. Take with water on an empty stomach or with a light meal. Some practitioners recommend splitting doses BID (morning + midday) for more stable exposure; this is reasonable for higher total doses. Avoid evening/night dosing for most users, particularly if you experience insomnia or restless sleep with NMN. If you take multiple supplements or medications, coordinate timing to avoid any pill-burden challenges but there are no significant timing-based interactions that require specific separation."
          }
        },
        {
          "@type": "Question",
          "name": "Does NMN cause any side effects?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "NMN has a favorable short-term safety profile. Reported side effects in clinical trials are generally mild and infrequent: GI upset (5-10%), occasional mild headache, mild insomnia with evening dosing, and rare flushing. No serious NMN-attributable adverse events have been reported in available trials. Long-term (>1 year) safety is less well-characterized because trials have generally been short. Theoretical concerns include methyl donor depletion (addressed by concurrent B-vitamin or TMG supplementation) and potential cancer substrate provision (avoid with active cancer). For most healthy adults, short-to-medium-term NMN use appears well-tolerated."
          }
        },
        {
          "@type": "Question",
          "name": "Is NMN still legal to buy in the US after the FDA determination?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "As of early 2026, NMN remains widely available from supplement retailers despite the FDA's late 2022 preliminary determination that NMN is not a lawful dietary supplement (because it had been studied as a drug prior to supplement marketing). The regulatory situation has continued to evolve with industry litigation, FDA enforcement discretion, and some product reformulation. Individual products have been pulled from some major retailers while remaining available from others. The legal status of buying NMN for personal use does not prevent individual purchase; the regulatory question primarily affects commercial marketing and distribution. Consumers can generally still purchase NMN from online retailers, compound pharmacies (with prescription), and some physical supplement stores. The long-term regulatory outcome remains uncertain."
          }
        },
        {
          "@type": "Question",
          "name": "Should I combine NMN with metformin or rapamycin?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Combinations of NMN with metformin or rapamycin (when available in our database) are popular in longevity-oriented protocols with plausible mechanistic rationale. Metformin activates AMPK and inhibits mitochondrial complex I; NMN elevates NAD+ and supports sirtuin activity; rapamycin inhibits mTORC1. These mechanisms converge on autophagy induction, improved metabolic flexibility, and anti-aging pathway activation. However, no controlled human trials have tested these combinations for longevity outcomes. Safety of combinations appears good based on individual agent profiles. For individuals pursuing comprehensive longevity pharmacology, the Sinclair/Attia-style stacks (metformin + NMN + rapamycin + resveratrol) are conceptually reasonable but evidence for marginal benefit of the combination over the most evidence-based single component (metformin) is absent. Individual choice with informed consent about the preliminary evidence state is appropriate."
          }
        },
        {
          "@type": "Question",
          "name": "Does NMN work better sublingually or in capsule form?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Controlled evidence comparing sublingual to oral NMN absorption and efficacy is limited. Theoretical arguments favor sublingual — bypassing intestinal degradation and first-pass metabolism. Practical evidence from available trials has primarily used oral capsule form and documented meaningful NAD+ elevation, suggesting oral absorption is adequate. Some users report subjectively faster onset with sublingual; others notice no difference. The added cost and practical inconvenience of sublingual forms may not be justified by the limited evidence of superior absorption. For most users, high-quality oral capsules are acceptable. For users specifically interested in sublingual, reputable sublingual powder products from vendors like DoNotAge, Renue, or Uthever are reasonable. Injectable NMN (compounded) provides the most direct systemic absorption but is not commercially available as a supplement and requires prescription and injection skill."
          }
        },
        {
          "@type": "Question",
          "name": "Can NMN help with energy, exercise performance, or cognitive function?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Modest evidence supports these applications. Liao et al. 2021 documented improved aerobic capacity (VO2max) in recreational runners taking NMN 300-1,200 mg/day for 6 weeks. Yoshino 2021 showed improved skeletal muscle gene expression related to muscle remodeling. Anecdotal reports of improved energy and cognitive clarity are common but not confirmed in controlled trials. Mechanistically, NAD+ is central to mitochondrial function and cellular energy metabolism, providing plausible basis for energy and performance benefits. For cognitive function specifically, preclinical evidence in aging mice shows NMN-mediated improvements in cerebromicrovascular function and cognitive performance. Human cognitive trials are limited. For individuals using NMN for energy or performance purposes, expect modest effects that may take weeks to develop. For exercise performance in already-trained healthy individuals, the effect magnitude is likely small. For older adults with age-related decline, effects may be more noticeable."
          }
        }
      ]
    },
    {
      "@context": "https://schema.org",
      "@type": "Organization",
      "@id": "https://www.bodyhackguide.co#organization",
      "name": "BodyHackGuide",
      "alternateName": "BHG",
      "url": "https://www.bodyhackguide.co",
      "logo": {
        "@type": "ImageObject",
        "url": "https://www.bodyhackguide.co/logo.png",
        "width": 512,
        "height": 512
      },
      "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.",
      "foundingDate": "2024",
      "founder": {
        "@id": "https://www.bodyhackguide.co/about#person"
      },
      "sameAs": [
        "https://x.com/bodyhackguide",
        "https://reddit.com/r/BodyHackGuide",
        "https://reddit.com/r/BrainHackGuide",
        "https://reddit.com/r/Biohackingher",
        "https://discord.gg/Mhq5UdRYBA"
      ],
      "knowsAbout": [
        "Peptide research",
        "Nootropic research",
        "Biohacking",
        "Compound dosing",
        "Vendor transparency"
      ],
      "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards",
      "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards",
      "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards"
    }
  ]
---

[Skip to content](#main-content)

## Research Use Only

This site is an **educational resource** for research compounds. We do **not endorse** human consumption of any compound. BodyHackGuide and **BHG Labs share common ownership**; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are **21 years of age or older** and agree to our [Terms](/terms) & [Privacy Policy](/privacy).

I'm 21+ — Enter SiteLeave site

  

[![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)BodyHackGuide ](/)

[Compare](/compare)[Wiki](/wiki)[Vendors](/vendors)[Deals](/deals)[Stacks](/stack-builder)[Nootropics](/nootropics)[Tools](/tools)

Learn

Community

Search ⌘K

[Sign In](/auth?returnTo=%2Fcompound%2Fnmn)

100K+ researchers trust BodyHackGuide — Join [r/BodyHackGuide](https://reddit.com/r/bodyhackguide) 

1.  [Home](/)
2.  [Compounds](/compare)
3.  NMN 

[Where to buy NMN](/buy/nmn) [NMN coupon codes](/coupons/nmn) [NMN protocol](/protocol/nmn) [Alternatives to NMN](/alternatives-to/nmn) [NMN side effects](/side-effects/nmn)

1.  [Home](/)

3.  [Compounds](/compare)

5.  NMN 

# NMN

Longevity Preclinical 

Download  PDF

Also known as: Nicotinamide Mononucleotide, beta-NMN, β-NMN, β-Nicotinamide mononucleotide, NMN-C, Uthever 

Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide derived from ribose and nicotinamide, serving as the direct biosynthetic precursor to nicotinamide adenine dinucleotide (NAD+) via a single enzymatic step catalyzed by nicotinamide mononucleotide adenylyltransferase (NMNAT). NMN is found in small quantities in foods including broccoli, cabbage, cucumber, edamame, avocado, tomato, and raw beef, typically in microgram-to-low-milligram quantities per serving — far below the 250-1000 mg doses used in supplementation research.

Last reviewed: May 4, 2026 

[

Longevity

Category



](/wiki#cat-longevity)

Preclinical

Research Stage

OverviewChemical InfoDosing & ProtocolsInteractionsResearchCompare PricesRelated

## Overview

### At A Glance

Mechanism 

NMN functions as a direct precursor to NAD+ (nicotinamide adenine dinucleotide) through the NAD+ salvage pathway. The conversion requires a single enzymatic step catalyzed by NMNAT (nicotinamide mononucleotide adenylyltransferase), which adenylates NMN using ATP to produce NAD+. … 

### Overview

Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide derived from ribose and nicotinamide, serving as the direct biosynthetic precursor to nicotinamide adenine dinucleotide (NAD+) via a single enzymatic step catalyzed by nicotinamide mononucleotide adenylyltransferase (NMNAT). NMN is found in small quantities in foods including broccoli, cabbage, cucumber, edamame, avocado, tomato, and raw beef, typically in microgram-to-low-milligram quantities per serving — far below the 250-1000 mg doses used in supplementation research. The structure — a ribonucleotide composed of ribose-5-phosphate linked to nicotinamide via a beta-N-glycosidic bond — makes NMN one step closer to NAD+ in the biosynthetic pathway than nicotinamide or nicotinamide riboside (NR), which are two and one-plus-ATP step further removed respectively. NMN's rise from obscure biochemistry reagent to one of the most commercially prominent longevity supplements began with preclinical work in the Sinclair and Imai laboratories documenting NAD+-lowering effects of aging and NAD+-repletion benefits of NMN administration in mice. Mills et al. 2016 (PMID 28068222) demonstrated that 12 months of oral NMN (100-300 mg/kg) in aged mice prevented age-associated physiologic decline including weight gain, insulin sensitivity deterioration, eye function decline, muscle function decline, and bone density loss. Similar findings came from multiple rodent studies over 2013-2020 establishing NMN as a consistent NAD+-raising intervention with broad preclinical benefit across age-related pathologies. The first human pharmacokinetic study of NMN was conducted by Irie and colleagues in 2020, administering single oral doses of 100, 250, and 500 mg NMN to ten healthy Japanese men aged 40-60 and documenting dose-proportional increases in plasma NMN and its downstream metabolites with no serious adverse events — establishing oral NMN's basic safety and pharmacokinetics in humans. Yoshino and colleagues 2021 (PMID 33888596) conducted the first human efficacy RCT, randomizing 25 prediabetic postmenopausal women with overweight/obesity to 10 weeks of oral NMN 250 mg/day versus placebo. The trial documented significant improvement in skeletal muscle insulin sensitivity (measured by hyperinsulinemic-euglycemic clamp) with NMN versus placebo, and increased skeletal muscle expression of genes related to muscle remodeling. The Yoshino 2021 trial remains the landmark early human NMN efficacy study despite its small sample size. Subsequent human trials have examined NMN across a range of populations and outcomes with varying results: Yamamoto 2022 examined NMN in older adults with mixed metabolic outcomes; Pencina 2023provided a 6-week dose-ranging safety study; Connell et al. 2023conducted a meta-analysis of available NMN human trials through early 2023. The emerging human evidence base supports NMN's safety across tested dose ranges (up to 1,000 mg/day for short-term use in small trials) and provides suggestive but not yet definitive evidence for metabolic, cardiovascular, and musculoskeletal benefits. The evidence base remains substantially behind the marketing claims, with many commercial NMN products citing preclinical mouse data or extrapolating from NAD+ biology rather than demonstrating human RCT outcomes. Regulatory status: NMN was marketed in the US as a dietary supplement under DSHEA from approximately 2014 onward. In late 2022, the FDA issued a preliminary determination that NMN is not a lawful dietary supplement because it had been studied as a drug prior to being marketed as a supplement, potentially excluding it from DSHEA protection. This triggered significant industry concern and some reformulation. The regulatory situation has continued to evolve through 2025-2026 with industry litigation and FDA enforcement activity varying by product and distributor. As of early 2026, NMN remains widely available from many supplement retailers despite the regulatory uncertainty. NAD+ biochemistry context: NAD+ is a central coenzyme in cellular metabolism, participating in hundreds of enzymatic reactions spanning energy metabolism (as electron carrier in oxidative phosphorylation), DNA repair (as substrate for poly-ADP-ribose polymerase or PARP enzymes), and signaling (as substrate for sirtuins and CD38). Cellular NAD+ levels decline with aging across multiple tissues and organisms, with the decline implicated in age-associated mitochondrial dysfunction, impaired DNA repair, reduced sirtuin activity, and compromised cellular resilience. The NAD+ "boosting" hypothesis — that restoring youthful NAD+ levels through precursor supplementation could slow or reverse age-related decline — has driven extensive investment in NMN and the related NAD+ precursor nicotinamide riboside (NR, marketed as Niagen). NMN and NR are often discussed as competing or complementary precursors; both have human safety data and both raise NAD+ in humans, though the optimal dose, route, and clinical context remain areas of active research and commercial dispute. This entry covers NMN's biosynthesis and relationship to the NAD+ salvage pathway; the human and preclinical evidence base for metabolic, cardiovascular, and cognitive applications; dose-response considerations and the rational approach to supplementation; the oral versus sublingual versus injectable administration route debate; the evolving regulatory landscape; appropriate integration into complete longevity protocols alongside [metformin](/compound/metformin), [rapamycin](/compound/rapamycin) (when available), [NAD+](/compound/nad), and lifestyle interventions; and honest framing that despite strong mechanistic rationale and good safety data, definitive evidence for meaningful longevity or healthspan extension in humans remains to be established.

## Chemical Information

IUPAC Name

Not yet available 

CAS Number

Not yet available 

Molecular Formula

Not yet available 

Molecular Mass

Not yet available 

Chemical data is being compiled for this compound.

## Dosing & Protocols

### Unlock Dosing Protocols

Free account gets you:

-   View beginner, intermediate & advanced protocols 
-   See weight-based dosing calculations 
-   Access cycle length & frequency data 

[Create free account](/auth)[Sign in](/auth)

2,800+ researchers already in

## Research

### Unlock Research Data

Free account gets you:

-   Browse PubMed study summaries 
-   See clinical trial phases & results 
-   Access mechanism of action details 

[Create free account](/auth)[Sign in](/auth)

2,800+ researchers already in

## Interactions

### Contraindications

NMN has a favorable short-term safety profile but specific populations warrant caution or avoidance. Absolute contraindications: Active cancer (avoid without oncology consultation — theoretical concerns about NAD+ as tumor substrate, though evidence is mixed); known hypersensitivity to NMN or related nucleotides. Relative contraindications (use with caution and specific monitoring): Pregnancy and breastfeeding — no safety data; avoid except in specifically authorized research contexts. Pediatric age — not studied; avoid outside specific clinical research. Chronic kidney disease stage 4-5 — theoretical concerns about impaired nucleotide clearance; limited data. Severe hepatic impairment — limited data; caution. Active chemotherapy or radiation therapy — discuss with oncology before concurrent use. Niacin flushing disorders — theoretical cross-reactivity concerns though rare. Immunosuppressive medication use — limited data on interactions. Specific medication interaction considerations: Chemotherapy with alkylating agents, platinum compounds, or topoisomerase inhibitors — theoretical interactions via DNA repair modulation (PARP substrate provision); discuss with oncology. Methotrexate and other methyl-dependent medications — theoretical methyl pool effects; limited clinical significance. Immunosuppressants — limited interaction data. Specific clinical situations: New unexplained weight gain, new GI symptoms, unexplained fatigue, abnormal lab findings during NMN use warrant discontinuation and evaluation. Persistent insomnia or mood changes warrant timing adjustment or discontinuation. Development of new cardiovascular symptoms warrants evaluation. Monitoring: Baseline metabolic panel, HbA1c, lipid panel, complete blood count before starting NMN at higher doses (>500 mg/day) is prudent. Annual monitoring during chronic use. Blood pressure monitoring during initial 4-8 weeks. Specific biomarker tracking (NAD+ levels, epigenetic clocks, inflammatory markers) is optional and research-adjacent. Practical considerations for surgical, diagnostic, or medical procedures: NMN can generally be continued during outpatient procedures. For major surgery, 1-week hold is conservative practice without strong evidence-base. No specific monitoring required beyond standard pre-operative labs. Emergency considerations: NMN overdose has not been reported. In theory, very high doses (>5,000 mg) might produce nausea, GI upset, and transient metabolic effects but would be expected to resolve quickly given the rapid nicotinamide metabolism. Symptoms requiring emergency evaluation are unlikely from NMN alone but could reflect underlying conditions worth evaluating. Quality-control considerations: Substandard NMN products (insufficient actual NMN, contamination, degradation products) are a meaningful practical concern. Use reputable brands with third-party testing. Avoid extremely cheap or unknown-source products. Store appropriately and discard expired products.

Research Disclaimer

This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

[Sign in for alerts ](/auth)

No listings found for NMN.

Get NMN Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it.

[Sign in to set alerts](/auth)

### Sign in to leave a review

Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with NMN.

[Sign in](/auth)

### Related Compounds

[View All](/wiki)

[

### Cortagen

Longevity Preclinical 

Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) from the Khavinson bioregulator family developed at the St.

t½ Unknown (tetrapeptide; estimated <4 hours)  0 

Preclinical View Profile 

](/compound/cortagen)[

### NAD+

Longevity Phase II 

NAD+ (nicotinamide adenine dinucleotide, oxidized form) is a pyridine dinucleotide coenzyme essential to energy metabolism, DNA repair via PARP enzymes, sirtuin-mediated gene regulation, and calcium signaling via CD38.

t½ Varies by form: NR ~8 hours plasma; NMN ~1-2 hours plasma; IV NAD+ infusion dose-dependent  Oral precursors: NR 300-2,000 mg/day, NMN 250-900 mg/day, NAM 500-1,500 mg/day; IV NAD+ 500-1,500 mg per session. 

75447 studies View Profile 

](/compound/nad)[

### Rapamycin

Longevity Preclinical 

Rapamycin is a macrocyclic lactone antibiotic discovered in 1972 in soil samples from Rapa Nui (Easter Island) by a bacteriology survey team investigating indigenous Streptomyces species.

Preclinical View Profile 

](/compound/rapamycin)

### Side-by-Side Comparisons

[All Comparisons](/compare)

[NMN vs NAD+](/compare/nmn-vs-nad "NMN vs NAD")[NMN vs Coenzyme Q10](/compare/coq10-vs-nmn "COQ10 vs NMN")[NMN vs Urolithin A](/compare/urolithin-a-vs-nmn "Urolithin A vs NMN")[NMN vs MOTS-c](/compare/mots-c-vs-nmn "MOTS C vs NMN")

[

View Full Dosage Guide →

Protocols, calculator & safety for NMN



](/guides/dosage/nmn)

### Related Articles

[All Posts](/blog)

[

#### NAD+ in Longevity and Metabolic Research: A Complete Reference

NAD+ (nicotinamide adenine dinucleotide) is a redox coenzyme found in every living cell that shuttles electrons through energy metabolism and also serves as the fuel consumed by sirtuins and PARP DNA-repair enzymes. It is central to longevity research because cellular NAD+ levels fall with age, and that decline is tied to mitochondrial function, DNA-repair signaling, and metabolism. Most evidence is preclinical or early-stage human, and these are research compounds, not products for human consumption.

7/1/2026 ](/blog/nad-plus-longevity-research-guide)

### Research Score

15 

0 PubMed studies

### Quality Indicators

Data Completeness

50% 

Description 

Mechanism of Action 

Chemical Data 

Dosing Protocols 

Safety Profile 

PubMed Studies 

Interactions 

Vendor Listings 

### Quick Facts

Trial Phase

Preclinical

[Full Dosage Guide](/guides/dosage/nmn)[Calculate Your Dose](/tools/reconstitution)

Research Disclaimer

This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.

## Frequently Asked Questions

Does NMN actually work in humans?

The short answer is: probably yes for modest metabolic and functional benefits, but the evidence base for meaningful longevity or healthspan extension in humans remains preliminary. The Yoshino 2021 trial (PMID 33888596) documented improved insulin sensitivity in prediabetic postmenopausal women with 10 weeks of 250 mg/day NMN. Liao 2021 showed aerobic capacity improvements in recreational runners. Pencina 2023 (PMID 37378613) confirmed safety and dose-proportional NAD+ elevation. These and other small trials support that oral NMN elevates NAD+ and produces some functional benefits. However, meaningful lifespan or healthspan extension requires long-term trials (multiple years, large populations) that have not been conducted. NMN's evidence base currently supports it as a plausible metabolic and functional intervention with modest effect sizes, rather than a proven anti-aging therapy. See [/compound/metformin](/compound/metformin) for the most evidence-supported longevity-adjacent pharmaceutical.

Is NMN the same as NR (nicotinamide riboside)?

NMN and NR are related but distinct NAD+ precursors with similar overall effects. NR is one step further from NAD+ in the biosynthetic pathway and requires conversion to NMN via the NRK1/2 enzymes before becoming NAD+. NMN converts to NAD+ via NMNAT in a single step. Both are absorbed orally and elevate NAD+; both have favorable safety profiles; both have human clinical trials supporting metabolic and functional benefits. Commercial positioning presents them as competing products, but the biochemistry suggests they are largely interchangeable with minor pharmacokinetic differences. NR (marketed as Tru Niagen) has a somewhat larger human clinical trial base due to earlier commercialization. NMN has received more Sinclair-lab-associated research. For practical purposes, either is a reasonable NAD+ precursor choice. Some practitioners rotate or combine them; evidence that this is superior to monotherapy is limited. See [/compound/nad](/compound/nad) for related discussion.

What dose of NMN should I take?

The standard dose range is 250-1,000 mg/day for most users. 250 mg/day is the Yoshino 2021 trial dose and is a reasonable entry dose. 500 mg/day is a common intermediate dose. 1,000 mg/day approaches the upper end of tested doses. Morning dosing is preferred to support circadian alignment. Take with water; food is optional. Doses above 1,000-2,000 mg/day have not shown additional benefit in available trials and may increase theoretical methyl-depletion concerns. For injectable NMN (compounded), 100-300 mg SC daily or several times weekly is typical but is not a standard consumer product. Quality matters — use reputable brands with third-party testing.

Will NMN help me live longer?

Honestly, unclear. Preclinical data in mice shows consistent lifespan extension of 5-15% with NMN and related NAD+ precursors, which is real but modest. Human lifespan extension requires trials that span multiple years in large populations, which have not been conducted for NMN. Short-term human trials (6-12 weeks) show modest metabolic and functional benefits, which plausibly translate to healthspan benefits if sustained, but this extrapolation is uncertain. Comparing NMN to interventions with stronger longevity evidence: exercise has robust epidemiologic and RCT-level evidence for reduced mortality; Mediterranean or plant-predominant diets have strong evidence; not smoking has very strong evidence; maintained social connection has good evidence. NMN is potentially additive to these foundational interventions but is not a replacement. The honest answer is that NMN may contribute modestly to healthspan-relevant physiology, but the magnitude of effect on lifespan in humans is unknown and likely small-to-moderate.

What is the best time of day to take NMN?

Morning dosing is generally recommended because NAD+ naturally peaks in the morning, aligning supplementation with endogenous circadian rhythm. NAD+ may produce mild alertness effects that can disrupt sleep for some users if taken in the evening. Take with water on an empty stomach or with a light meal. Some practitioners recommend splitting doses BID (morning + midday) for more stable exposure; this is reasonable for higher total doses. Avoid evening/night dosing for most users, particularly if you experience insomnia or restless sleep with NMN. If you take multiple supplements or medications, coordinate timing to avoid any pill-burden challenges but there are no significant timing-based interactions that require specific separation.

Does NMN cause any side effects?

NMN has a favorable short-term safety profile. Reported side effects in clinical trials are generally mild and infrequent: GI upset (5-10%), occasional mild headache, mild insomnia with evening dosing, and rare flushing. No serious NMN-attributable adverse events have been reported in available trials. Long-term (>1 year) safety is less well-characterized because trials have generally been short. Theoretical concerns include methyl donor depletion (addressed by concurrent B-vitamin or TMG supplementation) and potential cancer substrate provision (avoid with active cancer). For most healthy adults, short-to-medium-term NMN use appears well-tolerated.

Is NMN still legal to buy in the US after the FDA determination?

As of early 2026, NMN remains widely available from supplement retailers despite the FDA's late 2022 preliminary determination that NMN is not a lawful dietary supplement (because it had been studied as a drug prior to supplement marketing). The regulatory situation has continued to evolve with industry litigation, FDA enforcement discretion, and some product reformulation. Individual products have been pulled from some major retailers while remaining available from others. The legal status of buying NMN for personal use does not prevent individual purchase; the regulatory question primarily affects commercial marketing and distribution. Consumers can generally still purchase NMN from online retailers, compound pharmacies (with prescription), and some physical supplement stores. The long-term regulatory outcome remains uncertain.

Should I combine NMN with metformin or rapamycin?

Combinations of NMN with [metformin](/compound/metformin) or [rapamycin](/compound/rapamycin) (when available in our database) are popular in longevity-oriented protocols with plausible mechanistic rationale. Metformin activates AMPK and inhibits mitochondrial complex I; NMN elevates NAD+ and supports sirtuin activity; rapamycin inhibits mTORC1. These mechanisms converge on autophagy induction, improved metabolic flexibility, and anti-aging pathway activation. However, no controlled human trials have tested these combinations for longevity outcomes. Safety of combinations appears good based on individual agent profiles. For individuals pursuing comprehensive longevity pharmacology, the Sinclair/Attia-style stacks (metformin + NMN + rapamycin + resveratrol) are conceptually reasonable but evidence for marginal benefit of the combination over the most evidence-based single component (metformin) is absent. Individual choice with informed consent about the preliminary evidence state is appropriate.

Does NMN work better sublingually or in capsule form?

Controlled evidence comparing sublingual to oral NMN absorption and efficacy is limited. Theoretical arguments favor sublingual — bypassing intestinal degradation and first-pass metabolism. Practical evidence from available trials has primarily used oral capsule form and documented meaningful NAD+ elevation, suggesting oral absorption is adequate. Some users report subjectively faster onset with sublingual; others notice no difference. The added cost and practical inconvenience of sublingual forms may not be justified by the limited evidence of superior absorption. For most users, high-quality oral capsules are acceptable. For users specifically interested in sublingual, reputable sublingual powder products from vendors like DoNotAge, Renue, or Uthever are reasonable. Injectable NMN (compounded) provides the most direct systemic absorption but is not commercially available as a supplement and requires prescription and injection skill.

Can NMN help with energy, exercise performance, or cognitive function?

Modest evidence supports these applications. Liao et al. 2021 documented improved aerobic capacity (VO2max) in recreational runners taking NMN 300-1,200 mg/day for 6 weeks. Yoshino 2021 showed improved skeletal muscle gene expression related to muscle remodeling. Anecdotal reports of improved energy and cognitive clarity are common but not confirmed in controlled trials. Mechanistically, NAD+ is central to mitochondrial function and cellular energy metabolism, providing plausible basis for energy and performance benefits. For cognitive function specifically, preclinical evidence in aging mice shows NMN-mediated improvements in cerebromicrovascular function and cognitive performance. Human cognitive trials are limited. For individuals using NMN for energy or performance purposes, expect modest effects that may take weeks to develop. For exercise performance in already-trained healthy individuals, the effect magnitude is likely small. For older adults with age-related decline, effects may be more noticeable.

## Research Tools

[

### Peptide Calculator

Reconstitution & syringe units



](/tools/reconstitution)[

### Reconstitution Guide

How to mix, step by step



](/guides/how-to-reconstitute-peptides)[

### Nasal Spray Calc

mL per actuation



](/tools/intranasal)[

### Half-Life Visualizer

Decay curves



](/tools/halflife)

## Related Compounds

[View All](/wiki)

[

### Cortagen

Longevity Preclinical 

Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) from the Khavinson bioregulator family developed at the St.

t½ Unknown (tetrapeptide; estimated <4 hours)  0 

Preclinical View Profile 

](/compound/cortagen)[

### NAD+

Longevity Phase II 

NAD+ (nicotinamide adenine dinucleotide, oxidized form) is a pyridine dinucleotide coenzyme essential to energy metabolism, DNA repair via PARP enzymes, sirtuin-mediated gene regulation, and calcium signaling via CD38.

t½ Varies by form: NR ~8 hours plasma; NMN ~1-2 hours plasma; IV NAD+ infusion dose-dependent  Oral precursors: NR 300-2,000 mg/day, NMN 250-900 mg/day, NAM 500-1,500 mg/day; IV NAD+ 500-1,500 mg per session. 

75447 studies View Profile 

](/compound/nad)[

### Rapamycin

Longevity Preclinical 

Rapamycin is a macrocyclic lactone antibiotic discovered in 1972 in soil samples from Rapa Nui (Easter Island) by a bacteriology survey team investigating indigenous Streptomyces species.

Preclinical View Profile 

](/compound/rapamycin)

## Side-by-Side Comparisons

[All Comparisons](/compare)

Compare NMN head-to-head: mechanism, half-life, dosing, safety, and live pricing.

[NMN vs NAD+](/compare/nmn-vs-nad "NMN vs NAD")[NMN vs Coenzyme Q10](/compare/coq10-vs-nmn "COQ10 vs NMN")[NMN vs Urolithin A](/compare/urolithin-a-vs-nmn "Urolithin A vs NMN")[NMN vs MOTS-c](/compare/mots-c-vs-nmn "MOTS C vs NMN")

Free 2026 Peptide Cheat Sheet — 50 pages, PDF

Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one.

[Download Free](/guides/peptide-cheat-sheet-download?utm_source=compound-nmn)

### Need bloodwork before starting?

Full hormone + metabolic panels from Anabolic Insights. Code CHONCH  for first-order discount.

[Order Bloodwork](https://anabolicinsights.ai/?ref=nwm2zjb)

![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)

### BodyHackGuide

Your biohacking research hub — compound pricing, brain health protocols, dosing tools, and vendor reviews.

[support@bodyhackguide.co](mailto:support@bodyhackguide.co)

[](https://discord.gg/Mhq5UdRYBA)[](https://reddit.com/r/BodyHackGuide)[](https://x.com/bodyhackguide)

Explore

#### Explore

-   [Compare prices](/compare)
-   [Research suppliers](/vendors)
-   [Deals](/deals)
-   [Coupons](/coupons)
-   [Nootropics](/nootropics)
-   [Brain health](/brain-health)
-   [Blog](/blog)
-   [Guides](/guides)

Tools

#### Tools

-   [Reconstitution](/tools/reconstitution)
-   [Dosage calculator](/tools/dosage)
-   [Half-life visualizer](/tools/halflife)
-   [COA lookup](/tools/coa)
-   [Cost calculator](/tools/cost-calculator)
-   [Stack builder](/stack-builder)
-   [All tools →](/tools)

Trust & vendors

#### Trust & vendors

-   [Vendor directory](/vendors)
-   [Trust scorecard](/vendors/scorecard)
-   [Get BHG verified](/vendors/get-vetted)
-   [Scoring methodology](/vendors/methodology)
-   [Peptide cheatsheet](/guides/peptide-cheat-sheet-download)

Company

#### Company

-   [About](/about)
-   [Affiliate disclosure](/affiliate-disclosure)
-   [Editorial standards](/editorial-standards)
-   [Creators](/creators)
-   [Coaches](/coaches)
-   [Privacy](/privacy)
-   [Terms](/terms)
-   [Full site directory →](/site-directory)

**Ownership & Affiliate Disclosure:** BodyHackGuide and BHG Labs share common ownership. We rank every vendor on the same public, reproducible [methodology](/vendors/methodology), and we earn a commission from purchases made through our links at no extra cost to you. Full details in our [affiliate disclosure](/affiliate-disclosure).

**Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell, distribute, or promote any products. Always consult a qualified healthcare professional and comply with local regulations.

© 2026 BodyHackGuide. All rights reserved. · [Terms](/terms) · [Privacy](/privacy)

hi 👋